Back to top
more

Reata Pharmaceuticals, Inc. (RETA)

(Delayed Data from NSDQ)

$80.41 USD

80.41
117,440

+2.31 (2.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $80.37 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reata (RETA) Q2 Earnings Top, Omaveloxolone Setback Hurts

by Zacks Equity Research

Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.

Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 8.56% and 111.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

by Kinjel Shah

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

Reata Surges on $350 Million Investment Deal With Blackstone

by Zacks Equity Research

Reata (RETA) announces a royalty and equity investment deal with Blackstone Group, which will support development of its lead pipeline candidate, bardoxolone methyl, in chronic kidney diseases.

Why Is Reata Pharmaceuticals, Inc. (RETA) Down 19.8% Since Last Earnings Report?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reata (RETA) Q1 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Reata (RETA) reports narrower-than-expected loss but misses revenue estimates for first-quarter 2020. Shares down.

Reata Pharmaceuticals Inc (RETA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Reata Pharmaceuticals Inc (RETA) delivered earnings and revenue surprises of 54.82% and -53.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Reata (RETA) Stock Might be a Great Pick

by Zacks Equity Research

Reata (RETA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Reata Pharmaceuticals, Inc. (RETA) Down 37.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -5.60% and 5.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q3 Earnings Expected to Decline

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reata (RETA) Jumps: Stock Rises 5. 6%

by Zacks Equity Research

Reata (RETA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Reata Successfully Completes Neuromuscular Disorder Study

by Zacks Equity Research

Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.

Is the Options Market Predicting a Spike in Reata Pharmaceuticals (RETA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Reata Pharmaceuticals (RETA) stock based on the movements in the options market lately.

Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.79% and 0.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Reata's (RETA) Kidney Candidate Gets Orphan Drug Status

by Zacks Equity Research

The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.

Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.03% and -1.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Reata Pharmaceuticals, Inc. (RETA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -30.49% and -45.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Reata Pharmaceuticals (RETA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Reata Pharmaceuticals (RETA) stock based on the movements in the options market lately.

    Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -40.54% and -16.89%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug

      by Zacks Equity Research

      The biotech sector is in focus as bigwig Biogen gains on better-than-expected Q2 results. Others like Gilead, Amgen and Celgene too are slated to report shortly.

        Can The Uptrend Continue for Reata Pharmaceuticals (RETA)?

        by Zacks Equity Research

        Investors certainly have to be happy with Reata Pharmaceuticals, Inc. (RETA) and its short term performance.

          Is a Surprise Coming for Reata Pharmaceuticals (RETA) This Earnings Season?

          by Zacks Equity Research

          Reata Pharmaceuticals (RETA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

            New Strong Sell Stocks for September 15th

            by Zacks Equity Research

            Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: